What research is your doctor going to undertake to find out if this might be the same process that starts the inflammation in your arteries leading to atheroscelerosis? And then research how to stop that inflammation. This is precisely why we need a stroke strategy. The answers are out there, we just need to direct our researchers to answer the correct questions. It is so blastedly simple I do have to wonder if our stroke leadership has any brains at all.
http://www.alphagalileo.org/ViewItem.aspx?ItemId=157463&CultureCode=en
Junior Scientist from the Jena University develops a test system for
the search for new active ingredients: Dr. Ulrike Garscha and her
colleagues from Jena together with scientists from the Karolinska
Institute in Stockholm published their results in the science magazine
'FASEB Journal'. In this they report on how they were able to study in
detail the mechanism through which the enzyme 5-Lipoxygenase together
with another protein called FLAP starts inflammation processes (DOI:
10.1096/fj.15-278010).
Asthma bronchiale, hayfever or neurodermatitis – allegies are on the
increase in Western European industrial countries. According to the
Robert-Koch-Institute every third adult falls ill with an allergy at
least once in their lives. The reasons for allergic reactions are
inflammation processes of the immune system. The enzyme 5-Lipoxygenase,
or in short, 5-LO, plays a pivotal role in this. “This enzyme regulates
the inflammation activities by catalyzing the biosynthesis of
pro-inflammatory mediators,“ as Dr. Ulrike Garscha of the Friedrich
Schiller University Jena (Germany) says. Therefore, the 5-LO would be a
promising target for active compounds in the treatment of inflammatory
diseases. However, the pharmacist concedes, there is only one approved
pharmaceutical on the US market, and due to serious side-effects it can
only be used to a very limited extend.
The Jena junior scientists from the Chair for Pharmaceutical and
Medical Chemistry and their small team now have worked out a new
approach, which can considerably advance the search for drugs in this
area. Ulrike Garscha and her colleagues from Jena together with
scientists from the Karolinska Institute in Stockholm published their
account of their research in the well-known science magazine 'FASEB
Journal'. In this they report on how they were able to study in detail
the mechanism through which the 5-LO together with another protein
called FLAP starts the inflammation processes (DOI:
10.1096/fj.15-278010).
To be able to do so, the researchers have developed a cellular system
on which they worked for years and which allows them to watch the
unfolding processes time-resolved and in high precision. Thus the
researchers provide a method through which tests for appropriate
candidates for active compounds can be much more finely targeted. “For
some years there has been the assumption that 5-LO and FLAP interact,“
stresses Prof. Dr. Oliver Werz from the University Jena, at whose chair
Dr. Garscha's team works. As soon as a cell of the immune system
receives an inflammation signal, the 5-LO, which normally moves freely
within the cell, wanders to the membrane of the cell nucleus and
interacts there with FLAP. “Only when they are associated with each
other the two molecules are able to unfold their impact and to start an
inflammation,“ says Werz.
Although this assembly has been widely acknowledged by the
international scientific community it has until now never been
established conclusively: The Jena pharmacists were the first to prove
it. To this end they made the interaction of the partaking proteins in
human immune cells visible through fluorescent dye and observed the
result by microscopy. Thus the scientists were also able to clarify the
exact regulatory mechanism through which the two molecules control the
inflammatory process. “While to start with in the first minutes of the
interaction a flexible complex from both molecules is formed, which
induces the synthesis of pro-inflammatory substances, after two to three
minutes a stable assembly of 5-LO and FLAP is formed, which decreases
the activity of the enzymes again,“ Ulrike Garscha explains. The 36 year
old junior scientist is convinced that new therapeutic approaches in
the treatment of inflammatory diseases will derive from these findings
in the long run.
http://www.uni-jena.de/en/Research+News/PM151019_Garscha_en.html
No comments:
Post a Comment